CompletedNot Applicable

Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-

Japan696 participantsStarted 2015-06-15

Plain-language summary

This study aims to understand the following items in post-marketing actual clinical settings to evaluate the safety of 13vPnC administered as a single dose in the elderly (adults aged 65 years or older). 1. To confirm the use in actual clinical settings 2. To confirm the occurrence of adverse events

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Geriatric patients vaccinated with this product (adult not younger than 65 years)
✓. Consent of vaccine recipients \[Vaccine recipient (or his/her legally acceptable representative) must sign and date the consent form warranting that the relevant information concerning this Study was appropriately communicated to the recipient\].

What they're measuring

Number of Participants With Adverse Reactions

Timeframe: 28 days

Trial details

NCT IDNCT03014206

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2017-01-31

Results submitted2018-01-30

View on ClinicalTrials.gov More Adult Not Younger Than 65 Years trials